Aiming to spare the anus: a new strategy for early rectal cancer
NCT ID NCT06949098
First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time
Summary
This trial is testing a combination of local tumor removal and chemoradiotherapy (radiation plus capecitabine chemotherapy) in people with early-stage rectal cancer located low in the rectum. The goal is to see if this approach can effectively treat the cancer while avoiding the need for a permanent colostomy, preserving the anus. The study will enroll 60 adults with stage I rectal cancer who strongly prefer to keep their anus. Researchers will track how many patients remain free of cancer recurrence for five years after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Local tumor resection followed by chemoradiotherapy (pelvic radiation plus capecitabine chemotherapy)
- What this could lead to
- If successful, this approach could offer a way to treat early-stage rectal cancer without removing the anus, preserving quality of life.
- What could go wrong
- This is an early-phase, single-center trial with a small number of patients. The treatment may not control the cancer as well as standard surgery, and there are risks from radiation and chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY-STAGE LOW/ULTRA-LOW RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Fourth Hospital of Hebei Medical University
RECRUITINGShijiazhuang, Hebei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.